Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Immunovia appoints Norma Alonzo Palma as new Vice President of Clinical and Medical Affairs

LUND (SWEDEN) – Immunovia (IMMNOV: Nasdaq Stockholm), the diagnostics company with the mission to increase pancreatic cancer survival rates through early detection, today announces the appointment of Norma Alonzo Palma, PhD as Vice President of Clinical and Medical Affairs.    As announced in July 2023, Immunovia significantly restructured to focus its resources on the company’s next-generation blood test for early detection of pancreatic cancer. After Immunovia successfully completed the discovery phase of the new test in November 2023, Norma’s appointment will enable Immunovia to

New number of votes in Bonava AB due to conversion

The number of votes in Bonava AB has changed due to conversion of 85,029 Class A shares to 85,029 Class B shares. The number of votes in the company hereby amounts to 208,064,499.According to Bonava’s articles of association, owner of a Class A share has the right to request that such share is converted to a Class B share. Each Class A share carries ten votes and each Class B share one vote. In January, a total of 85,029 Class A shares were converted to a total of 85,029 Class B shares at the request of shareholders. Following the conversions, there were as of 31 January 2024, the last

Conversion of shares in NCC AB, January 2024

According to NCC’s articles of association, owners of Series A shares are entitled to request that such shares be converted to Series B shares. Conversion reduces the total number of voting rights in the company.During January 2024, 62,397 Series A shares were converted to Series B shares at the request of shareholders, following which the total number of voting rights in the company amounts to 203,139,060. The total number of registered shares in the company amount to 99,760,956 of which 11,486,456 are Series A and 88,274,500 are Series B. NCC holds 2,099,221 Series B shares in treasury.

TactoTek® and BlueBinaries collaborate to expand IMSE® Technology bringing new light interfaces to upcoming automotive platforms

●     TactoTek® and BlueBinaries collaboration broadens the use of IMSE® (In-Mold Structural Electronics) technology in the Automotive  industry, facilitating the process from initial concept development to design execution for their licensees. ●     TactoTek's advancements introduce new platforms capable of producing distinct, clear lighting. This innovation paves the way for the creation of unique and visually striking user interfaces. ●        BlueBinaries' expertise in automotive optics, mechanical design, and electronics, complemented by TactoTek’s IMSE technology, opens avenues to

Invitation to CTEKs presentation of the year-end report

On February 7 at 09:00 CET, CTEK will hold an audiocast in English. CTEK is represented by CEO Henrik Fagrenius and CFO Thom Mathisen, who present the year-end report and answer questions. If you wish to participate via webcast, please use the link below. Via the webcast you can ask written questions. https://ir.financialhearings.com/ctek-q4-report-2023 If you wish to participate via teleconference, please register on the link below. After registration you will be provided with a phone number and a conference ID to access the conference. You can ask questions verbally via the

# 24-07 Annual Surveillance Report

Please find attached the Annual Surveillance Report from Nordic Growth Market NGM AB (NGM). The report covers how the market surveillance activities have been carried out during 2023 in accordance to chapter 5 in FFFS 2007:17. The Annual Surveillance Report is also available on the NGM website www.ngm.se, under the tab Market Surveillance/Reports. For more information about this Market Notice, please contact us by e-mail, marketsurveillance@ngm.se or telephone, +46 8 566 390 55. NGM Market Notice Pressroom https://news.cision.com/ngm-market-notice

Invitation to presentation of Scandic’s year-end report 2023

Scandic Hotels Group will present its year-end report for 2023 in a webcast at 09.00 CET on February 14, 2024. The report will be published at 07.30 CET on the same day.Scandic’s President & CEO and acting CFO Jens Mathiesen, will present the report in a webcast and telephone conference. The presentation is in English. Time: Wednesday, February 14, 2024 at 09.00 CET. Location: Webcast and telephone conference. Telephone numbers: Dial-in number to the telephone conference will be received by registering on the link below. After the registration you will be provided with phone

NE Group Debuts Enhanced Defender Crash Game

NE Group, a leading B2B iGaming software supplier, is thrilled to announce the launch of its latest version of the hugely popular sports-themed crash game, Defender.This new football-inspired game made its debut in 2022 and has undergone several user interface and design enhancements to elevate the gaming experience.  NE Group’s expert tech team has diligently optimised the game’s code and removed unnecessary intervals, resulting in significantly faster load times for a frictionless gaming experience, even on slower internet connections.  Defender now opens in a new window, enabling

Advenica receives an order worth 16 MSEK from a Swedish authority

Advenica has received an extended order from a Swedish authority. The deal is worth 16 MSEK, refers to services and the deliveries will take place continuously until January 2025.Advenica has extensive experience in working with customers who place very high demands on security technology – customers who demand solutions that protect the most sensitive information. A new order for services, such as maintenance, business intelligence and further development, linked to previously delivered encryption systems, has now been received from a Swedish authority. Delivery of the order will take

Outokumpu – Announcement regarding change in holdings

Outokumpu OyjStock exchange releaseJanuary 31, 2024 at 11.30 am EETOutokumpu – Announcement regarding change in holdings Outokumpu Oyj (business identity code: 0215254-2) has on January 30, 2024 received a notification based on Chapter 9, Section 5 of the Finnish Securities Market Act. Société Générale SA’s total holding in the shares and voting rights of Outokumpu has fallen below minimun threshold and was below minimun threshold on January 29, 2024. Their earlier holding in the Outokumpu shares and voting rights was 5.08%.   +----------------+----------+------------------+----

Invitation to media and analyst briefing for BioGaia Q4 2023 report

BioGaia's (NASDAQ: BIOG) financial report for the fourth quarter of 2023 will be published at approximately 8:00 AM CET on February 7, 2024. The company will issue a press release with the complete financial report attached, including tables. Following publication of the press release, the financial report will be available on BioGaia´s website . CEO Theresa Agnew and CFO Alexander Kotsinas will comment on the report and take questions at a live audiocast at 9:30 AM CET. To join the audiocast with teleconference and ask a

Vestas – Full-year 2023 conference call

Vestas Wind Systems A/S, Aarhus,Investor News, 31 January 2024 Vestas expects to disclose the Annual Report 2023 on 7 February 2024. On the day of the release, Vestas will host a conference call, in which our CEO and CFO will present the results via an audiocast, which can be followed live or replayed. The meeting will be held in English. Time7 February 2024 at 10.00 am CET (09.00 am GMT) AudiocastTo livestream or replay the presentation, go to Audiocast link . Q&AAt the end of the presentation, questions may be

Oncoinvent’s CEO to BioStock: “Radiopharmaceuticals has emerged as the hottest space in oncology”

Radiopharmaceuticals is a hot and emerging area that has attracted great interest from big pharma and investors in 2023, with several successful capital raises, IPOs and deals. A Nordic company within the field is Oncoinvent, based in Oslo and with lead candidate Radspherin in clinical development for the treatment of metastases in the peritoneal cavity from ovarian cancer and colorectal cancer.Read the full article at biostock.se : https://www.biostock.se/en/2024/01/oncoinvents-ceo-radiopharmaceuticals-has-emerged-as-the-hottest-space-in-oncology/ This is

Absolicon expands patent protection with US patent for automated quality control

Solar collectors for industrial thermal energy manufactured in Absolicon's production lines undergo automated quality control to guarantee the certified high performance. Absolicon was recently granted a U.S. patent that protects the basic principles of the quality control and is thereby extending the already extensive patent protection for its core technology and production processes.Absolicon's solar collectors consist of a unique technology, based on 20 years of research, for the extraction of thermal energy. The high performance of the solar collectors has been verified by the German

9.6 million SEK allocated for research on dogs, cats and other small pets

Are you interested in understanding the emotional bond between dog owners and their puppies or aging dogs? Perhaps you want to know whether the size of a puppy litter can serve as an indicator of a breed's health. Ten new research projects, recipients of funding from the Agria SKK Research Fund for 2024, are set to commence soon. These research initiatives, concentrating on dogs, cats, and other small pets, are conducted across Sweden, Norway, Denmark, Finland, and Germany. In total, there are 10 new projects and 9 ongoing ones, collectively sharing 9.6 million SEK. This year,

Invitation to presentation and Q&A of year end report 2023

Göteborg, Sweden — 31 January, 2024. Sleep Cycle AB (publ), the world’s leading sleep tracking application, will on the 8th of February, at 9:30 CET, present the year end report 2023 for shareholders, media and other stakeholders. Participants will be able to follow the presentation via webcast.Sleep Cycles CEO Erik Jivmark and CFO Per Andersson will present the report, which will be followed by a Q&A session. The presentation will be held in English. Link to webcast: https://ir.financialhearings.com/sleep-cycle-q4-2023 If you wish to participate via teleconference, please register on

Number of shares and votes in Medicover

The number of shares and votes in Medicover AB (publ) (“Medicover” or the “company”) has changed as a result of conversions of in total 6,975 class A shares into B shares carried out in January following requests from shareholders in accordance with the conversion clause in Medicover’s articles of association. Today, the last trading day of the month, there are in total 153,535,195 shares in Medicover, of which 76,664,401 are class A shares, together carrying 76,664,401 votes, 72,987,972 are class B shares, together carrying 7,298,797.2 votes and 3,882,822 are class C shares, together

First patient using Zeqmelit® in study ahead of market launch

The first patient in the AcuCort Phase IV study ZEQ001 has been assigned the oral film Zeqmelit®. The purpose of the study is to enhance marketing with practical experience from doctors and patients in connection with the launch in the Nordic region.The study will run concurrently with the Nordic market launch. In the study, allergy patients are assigned the company’s oral film Zeqmelit® for use when the need for treatment for acute allergic reactions arises. The goal of the study, which is an open-label non-randomized low-intervention study, is to obtain valuable data on the use of

Thinkproject appoints new non-executive Board Members: Darren Roos and Constance Minc; Darren Roos becomes new Chairperson

New board additions to accelerate Thinkproject’s expansion and growth plansPress release Munich, 31st January 2024 – Thinkproject, Europe’s leading SaaS platform for digital construction and asset management solutions, announces the appointment of two highly seasoned executives and industry leaders to its Board. The non-executive appointments of Darren Roos and Constance Minc will accelerate the company’s international expansion and growth aspirations.   Darren Roos will assume the role of Chairperson of the Board at Thinkproject. Roos is a proven enterprise software leader with a

Notification of managers’ and closely related parties’ transactions with Dampskibsselskabet NORDEN A/S’ shares in connection with share buy-back program

ANNOUNCEMENT NO. 26 - 31 JANUARY 2024   In connection with the announced share buy-back program in NORDEN, A/S Motortramp continuously sells shares pro rata and the market is to be informed accordingly – see the attached file and announcements nos. 186/23 and 187/23.   Kind regards, Dampskibsselskabet NORDEN A/S   Martin Badsted CFO     For further information: Stig Frederiksen, Head of Investor Relations, tel.: +45 32 71 08 55, e-mail: sfr@norden.com

BioStock: Evaxion to develop novel precision cancer vaccine concept

Evaxion Biotech has announced an expanded commitment to developing precision cancer vaccines by targeting a novel category of tumour antigens called endogenous retroviruses (ERVs). These will be identified with the company’s proprietary target discovery AI-Immunology platform, and proof-of-concept data is expected later this year.Read the article at biostock.se: Evaxion to develop novel precision cancer vaccine concept - BioStock This is a press release from BioStock - Connecting Innovation &

PONSSE Manager 2.0 gathers digital offering into one package

PONSSE Manager 2.0. is a next-generation digital service platform and forest machine management system that provides customers valuable data of machines’ location, productivity figures and fuel consumption, among others. The PONSSE Manager monitors the progress of stands, plans, and manages machine transportation, keep track of machine outputs according to assortment and print out measuring certificates."With the quick tempo of the modern world and the huge amount of data we see every day, finding the correct piece of information is often like trying to find a needle in the haystack. New

BioStock: Saniona raises capital to advance epilepsy programme

Saniona’s CEO Thomas Feldthus visited BioStock’s studio for an interview discussing the company’s drug development pipeline with epilepsy candidate SAN711 leading the way. We also learn more about the ongoing rights issue of approximately SEK 140 million and how Saniona plans on using the proceeds.Watch the interview with Saniona's CEO Thomas Feldthus at biostock.se: Saniona raises capital to advance epilepsy programme - BioStock This is a press release from BioStock - Connecting Innovation &

Alleima receives a major order for advanced tubes; umbilicals for the Oil and Gas segment

Alleima has received a major order for advanced tubes; umbilicals, for the Oil and Gas customer segment, to a total value of approximately SEK 520 million.The order is valued to approximately SEK 520 million will be used for an offshore project in South America. It is classified as a major order (i.e. above SEK 200 million) and will be reported in the Tube division. The order was booked in the first quarter of 2024 and deliveries are scheduled between the end of 2024 and the beginning of 2025. “Once again Alleima is chosen as a trusted supplier for high value-added products, umbilical

There are no items matching the current filter
There are no more items matching the current filter
Back to top